{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,6,11]],"date-time":"2024-06-11T08:32:04Z","timestamp":1718094724056},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2021,8,18]],"date-time":"2021-08-18T00:00:00Z","timestamp":1629244800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,8,18]],"date-time":"2021-08-18T00:00:00Z","timestamp":1629244800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Hematol"],"published-print":{"date-parts":[[2021,10]]},"DOI":"10.1007\/s12185-021-03186-8","type":"journal-article","created":{"date-parts":[[2021,8,18]],"date-time":"2021-08-18T14:03:20Z","timestamp":1629295400000},"page":"509-516","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Serial evaluation of the pharmacokinetics of ponatinib in patients with CML and Ph\u2009+\u2009ALL"],"prefix":"10.1007","volume":"114","author":[{"given":"Noriaki","family":"Kawano","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shinya","family":"Kimura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masatomo","family":"Miura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Taro","family":"Tochigi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takashi","family":"Nakaike","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kiyoshi","family":"Yamashita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koichi","family":"Mashiba","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ikuo","family":"Kikuchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naoto","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,8,18]]},"reference":[{"key":"3186_CR1","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/0002-9343(77)90124-3","volume":"63","author":"PJ Fialkow","year":"1977","unstructured":"Fialkow PJ, Jacobson RJ, Papayannopoulou T. Chronic myelocytic leukemia: clonal origin in a stem cell common to the granulocyte, erythrocyte, platelet and monocyte\/macrophage. Am J Med. 1977;63:125\u201330.","journal-title":"Am J Med"},{"key":"3186_CR2","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1056\/NEJM199907153410306","volume":"341","author":"S Faderl","year":"1999","unstructured":"Faderl S, Talpaz M, Estrov Z, O\u2019Brien S, Kurzrock R, Kantarjian HM. The biology of chronic myeloid leukemia. N Engl J Med. 1999;341:164\u201372.","journal-title":"N Engl J Med"},{"key":"3186_CR3","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1038\/243290a0","volume":"243","author":"JD Rowley","year":"1973","unstructured":"Rowley JD. Letter: a new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining. Nature. 1973;243:290\u20133.","journal-title":"Nature"},{"key":"3186_CR4","doi-asserted-by":"publisher","first-page":"2075","DOI":"10.1056\/NEJMoa1205127","volume":"367","author":"JE Cortes","year":"2012","unstructured":"Cortes JE, Kantarjian H, Shah NP, Bixby D, Mauro MJ, Flinn I, et al. Ponatinib in refractory Philadelphia chromosome-positive leukemias. N Engl J Med. 2012;367:2075\u201388.","journal-title":"N Engl J Med"},{"key":"3186_CR5","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1056\/NEJMoa022457","volume":"348","author":"SG O'Brien","year":"2003","unstructured":"O\u2019Brien SG, Guilhot F, Larson RA, Gathmann I, Baccarani M, Cervantes F, et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med. 2003;348:994\u20131004.","journal-title":"N Engl J Med"},{"key":"3186_CR6","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1016\/j.leukres.2010.10.027","volume":"35","author":"T Tauchi","year":"2011","unstructured":"Tauchi T, Kizaki M, Okamoto S, Tanaka H, Tanimoto M, Inokuchi K, et al. Seven-year follow-up of patients receiving imatinib for the treatment of newly diagnosed chronic myelogenous leukemia by the TARGET system. Leuk Res. 2011;35:585\u201390.","journal-title":"Leuk Res"},{"key":"3186_CR7","doi-asserted-by":"crossref","unstructured":"O'brien SG, Guilhot F, Goldman JM. International randomized study of interferon versus STI571 (IRIS) 7-year follow-up: sustained survival, low rate of transformation and increased rate of major molecular response (MMR) in patients (pts) with newly diagnosed chronic myeloid leukemia I chronic phase (CML-CP) treated with imatinib (IM). Blood (ASH Annual Meeting Abstracts). 2008;112:186. [abstract].","DOI":"10.1182\/blood.V112.11.186.186"},{"key":"3186_CR8","doi-asserted-by":"publisher","first-page":"2260","DOI":"10.1056\/NEJMoa1002315","volume":"362","author":"H Kantarjian","year":"2010","unstructured":"Kantarjian H, Shah NP, Hochhaus A, Cortes J, Shah S, Ayala M, et al. Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med. 2010;362:2260\u201370.","journal-title":"N Engl J Med"},{"key":"3186_CR9","doi-asserted-by":"publisher","first-page":"2251","DOI":"10.1056\/NEJMoa0912614","volume":"362","author":"G Saglio","year":"2010","unstructured":"Saglio G, Kim DW, Issaragrisil S, Coutre PL, Etienne G, Lobo C, et al. Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. N Engl J Med. 2010;362:2251\u20139.","journal-title":"N Engl J Med"},{"key":"3186_CR10","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1007\/s12185-013-1470-1","volume":"99","author":"S Fujisawa","year":"2014","unstructured":"Fujisawa S, Nakamae H, Ogura M, Ishizawa K, Taniwaki M, Utsunomiya A, et al. Efficacy and safety of dasatinib versus imatinib in Japanese patients with newly diagnosed chronic-phase chronic myeloid leukemia (CML-CP): subset analysis of the DASISION trial with 2-year follow-up. Int J Hematol. 2014;99:141\u201353.","journal-title":"Int J Hematol"},{"key":"3186_CR11","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1007\/s12185-011-0841-8","volume":"93","author":"H Nakamae","year":"2011","unstructured":"Nakamae H, Shibayama H, Kurokawa M, Fukuda T, Nakaseko C, Kanda Y, et al. Nilotinib as frontline therapy for patients with newly diagnosed Ph+ chronic myeloid leukemia in chronic phase: results from the Japanese subgroup of ENESTnd. Int J Hematol. 2011;93:624\u201332.","journal-title":"Int J Hematol"},{"key":"3186_CR12","doi-asserted-by":"publisher","first-page":"34","DOI":"10.3960\/jslrt.56.34","volume":"56","author":"N Kawano","year":"2016","unstructured":"Kawano N, Yoshida S, Kawano S, Takuro K, Yamashita K, Ochiai H, et al. Clinical features and treatment outcomes of 51 patients with chronic myeloid leukemia treated with a tyrosine kinase inhibitor at a single institution from 2002 to 2014. J Clin Exp Hematop. 2016;56:34\u201342.","journal-title":"J Clin Exp Hematop"},{"key":"3186_CR13","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1182\/blood-2016-09-739086","volume":"132","author":"JE Cortes","year":"2018","unstructured":"Cortes JE, Kim DW, Pinilla-Ibarz J, Lecoutre PD, Paquette R, Chuah C, et al. Ponatinib efficacy and safety in Philadelphia chromosome-positive leukemia: final 5-year results of the phase 2 PACE Trial. Blood. 2018;132:393\u2013404.","journal-title":"Blood"},{"key":"3186_CR14","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1007\/s12185-017-2238-9","volume":"106","author":"A Tojo","year":"2017","unstructured":"Tojo A, Kyo T, Yamamoto K, Nakamae H, Takahashi N, Kobayashi Y, et al. Ponatinib in Japanese patients with Philadelphia chromosome-positive leukemia, a phase 1\/2 study. Int J Hematol. 2017;106:385\u201397.","journal-title":"Int J Hematol"},{"key":"3186_CR15","doi-asserted-by":"publisher","first-page":"1495","DOI":"10.1038\/s41375-020-0842-9","volume":"34","author":"A Hochhaus","year":"2020","unstructured":"Hochhaus A, Breccia M, Saglio G, Garc\u00eda-Guti\u00e9rrez V, R\u00e9a D, Janssen J, et al. Expert opinion-management of chronic myeloid leukemia after resistance to second-generation tyrosine kinase inhibitors. Leukemia. 2020;34:1495\u2013502.","journal-title":"Leukemia"},{"key":"3186_CR16","doi-asserted-by":"publisher","first-page":"1786","DOI":"10.1182\/blood.2019004685","volume":"136","author":"N Saini","year":"2020","unstructured":"Saini N, Marin D, Ledesma C, Delgado R, Rondon G, Popat UR, et al. Impact of TKI maintenance post-allogeneic transplant in Philadelphia positive acute lymphoblastic leukemia. Blood. 2020;136:1786\u20139.","journal-title":"Blood"},{"key":"3186_CR17","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.leukres.2017.11.012","volume":"64","author":"M Abumiya","year":"2018","unstructured":"Abumiya M, Miura M, Takahashi N. Therapeutic drug monitoring of ponatinib using a simple high-performance liquid chromatography method in Japanese patients. Leuk Res. 2018;64:42\u20135.","journal-title":"Leuk Res"},{"key":"3186_CR18","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1007\/s12185-021-03156-0","volume":"114","author":"K Kidoguchi","year":"2021","unstructured":"Kidoguchi K, Ureshino H, Kizuka-Sano H, Yamaguchi K, Katsuya H, Kubota Y, et al. Efficacy and safety of ponatinib for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: a case series from a single institute. Int J Hematol. 2021;114:199\u2013204.","journal-title":"Int J Hematol"},{"key":"#cr-split#-3186_CR19.1","unstructured":"Shimoda k, Takahashi N, Kirito K, Iriyama N, Kawaguchi Y, Kizaki M. JSH practical guidelines for hematological malignancies, 2018: I. Leukemia-4. Chronic myeloid leukemia (CML)\/myeloproliferative neoplasms (MPN)."},{"key":"#cr-split#-3186_CR19.2","doi-asserted-by":"crossref","unstructured":"Int J Hematol. 2020;112:268-91.","DOI":"10.1007\/s12185-020-02964-0"},{"issue":"Suppl 2","key":"3186_CR20","doi-asserted-by":"publisher","first-page":"S141","DOI":"10.1007\/s00277-015-2322-2","volume":"94","author":"M Baccarani","year":"2015","unstructured":"Baccarani M, Castagnetti F, Gugliotta G, Rosti G. A review of the European Leukemia Net recommendations for the management of CML. Ann Hematol. 2015;94(Suppl 2):S141-147.","journal-title":"Ann Hematol"},{"key":"3186_CR21","doi-asserted-by":"publisher","first-page":"966","DOI":"10.1038\/s41375-020-0776-2","volume":"34","author":"A Hochhaus","year":"2020","unstructured":"Hochhaus A, Baccarani M, Silver RT, Schiffer C, Apperley JF, Cervantes F, et al. European Leukemia Net 2020 recommendations for treating chronic myeloid leukemia. Leukemia. 2020;34:966\u201384.","journal-title":"Leukemia"},{"key":"3186_CR22","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1007\/s12185-011-0956-y","volume":"94","author":"N Kawano","year":"2011","unstructured":"Kawano N, Okuda S, Yoshida S, Kugimiya H, Ito M, Horikawa N, et al. Successful treatment of lymphoid blastic crisis in chronic myelogenous leukemia with the additional bcr\/abl transcript using imatinib-combined chemotherapy and high-dose chemotherapy with allogeneic bone marrow stem cell transplantation. Int J Hematol. 2011;94:561\u20136.","journal-title":"Int J Hematol"},{"key":"3186_CR23","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1111\/ejh.13268","volume":"103","author":"K Nagafuji","year":"2019","unstructured":"Nagafuji K, Miyamoto T, Eto T, Ogawa R, Okumura H, Takase K, et al. Prospective evaluation of minimal residual disease monitoring to predict prognosis of adult patients with Ph-negative acute lymphoblastic leukemia. Eur J Haematol. 2019;103:164\u201371.","journal-title":"Eur J Haematol"},{"key":"3186_CR24","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1038\/s41409-018-0279-1","volume":"54","author":"J Sugita","year":"2019","unstructured":"Sugita J, Kagaya Y, Miyamoto T, Shibasaki Y, Nagafuji K, Ota S, et al. Myeloablative and reduced-intensity conditioning in HLA-haploidentical peripheral blood stem cell transplantation using post-transplant cyclophosphamide. Bone Marrow Transplant. 2019;54:432\u201341.","journal-title":"Bone Marrow Transplant"},{"key":"3186_CR25","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1016\/j.ccr.2009.09.028","volume":"16","author":"T O'Hare","year":"2009","unstructured":"O\u2019Hare T, Shakespeare WC, Zhu X, Eide CA, Rivera VM, Wang F, et al. AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance. Cancer Cell. 2009;16:401\u201312.","journal-title":"Cancer Cell"},{"key":"3186_CR26","doi-asserted-by":"publisher","unstructured":"Valentin GG, Michael WD, Maria RB, Vamsi KK, Luke A, Charles C, et al. The OPTIC study: a multicenter, randomized, phase 2 Trial to evaluate three starting doses of ponatinib with response-based dose reduction in patients with chronic phase chronic myeloid leukemia resistant to prior tyrosine kinase therapy, clinical lymphoma, myeloma. Leukemia. 2018;18:S228\u2013S229. https:\/\/doi.org\/10.1016\/j.clml.2018.07.104.","DOI":"10.1016\/j.clml.2018.07.104"},{"key":"3186_CR27","unstructured":"Cortes J. Interim analysis (IA) of OPTIC: a dose-ranging study of three ponatinib (PON) starting doses. In: American Society of Clinical Oncology Virtual Meeting (ASCO20; May 29\u2013May 31, 2020), 2020 Abstract #7502. 2020."},{"key":"3186_CR28","doi-asserted-by":"publisher","first-page":"2","DOI":"10.4172\/2572-4916.1000169","volume":"4","author":"F Sora","year":"2016","unstructured":"Sora F, Chiusolo P, Laurenti L, Soverini S, Sica S. Ponatinib before and after allogeneic stem cell transplantation for Ph+ acute lymphoblastic leukemia or lymphoid blast crisis of chronic myelogenous leukemia: a single-center experience. J Bone Res. 2016;4:2. https:\/\/doi.org\/10.4172\/2572-4916.1000169.","journal-title":"J Bone Res"},{"key":"3186_CR29","first-page":"1140","volume":"60","author":"M Miura","year":"2019","unstructured":"Miura M, Takahashi N. Management using the plasma concentration of tyrosine kinase inhibitors for the treatment of chronic myelogenous leukemia: an update. Rinsho Ketsueki. 2019;60:1140\u20137.","journal-title":"Rinsho Ketsueki"},{"key":"3186_CR30","doi-asserted-by":"publisher","first-page":"2745","DOI":"10.2169\/internalmedicine.4871-20","volume":"59","author":"Y Taniguchi","year":"2020","unstructured":"Taniguchi Y, Takahashi N, Miura M, Hirase C, Sueda S, Espinoza JL, et al. The impact of hemodialysis and liver cirrhosis on the plasma concentrations of tyrosine kinase inhibitors in a patient with chronic myeloid leukemia. Intern Med. 2020;59:2745\u20139.","journal-title":"Intern Med"}],"container-title":["International Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-021-03186-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12185-021-03186-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-021-03186-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,9]],"date-time":"2021-09-09T12:17:13Z","timestamp":1631189833000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12185-021-03186-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,18]]},"references-count":31,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021,10]]}},"alternative-id":["3186"],"URL":"https:\/\/doi.org\/10.1007\/s12185-021-03186-8","relation":{},"ISSN":["0925-5710","1865-3774"],"issn-type":[{"value":"0925-5710","type":"print"},{"value":"1865-3774","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,8,18]]},"assertion":[{"value":"19 March 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 June 2021","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 June 2021","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 August 2021","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors (Noriaki Kawano, Masatomo Miura, Taro Tochigi, Takashi Nakaike, Kiyoshi Yamashita, Koichi Mashiba, Ikuo Kikuchi) have no conflicts of interest to declare. Shinya Kimura reports that he has received speaker\u2019s fees from Novartis Pharmaceuticals, Grants and speaker\u2019s fees from Bristol Myers Squibb, Pfizer and Otsuka Pharmaceutical, Grants from Kyowa Hakko Kirin, Astellas Pharma, Chu-gai Pharmaceutical, Asahi Kasei Pharma, Nippon Shinyaku, Ono Pharmaceutical, Eisai Pharmaceuticals, Taiho, Pharmaceutical, Ohara pharmaceutical and Takeda outside of the submitted work. Naoto Takahashi reports that he has received Grants and speaker\u2019s fees from Novartis Pharmaceuticals, speaker\u2019s fees from Bristol Myers Squibb, Grants and speaker\u2019s fees from Pfizer, Grants and speaker\u2019s fees from Otsuka Pharmaceutical, Grants from Kyowa Hakko Kirin, Grants from Astellas Pharma, Grants from Chugai Pharmaceutical, Grants from Asahi Kasei Pharma, Grants from Ono Pharmaceutical, and Grants from Eisai Pharmaceuticals, outside of the submitted work. The remaining authors declare that they have no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}